期刊文献+

胰腺癌患者血清肿瘤标志物的检测及其临床意义 被引量:4

Assay and clinical significance of serum tumor markers in diagnosis of pancreatic carcinoma
原文传递
导出
摘要 目的观察胰腺癌患者血清肿瘤标志物的表达,分析其对胰腺癌诊断与预后判断的价值。方法采用化学发光法检测95例胰腺癌患者AFP、CEA、CA199、CA125和酶联免疫吸附方法检测CA242,并与80例其他系统恶性肿瘤患者和65例良性疾病患者作比较,同时对不同TNM分期的胰腺癌的五个指标比较。结果5种肿瘤标志物中CA199、CA125、CA242对胰腺癌的诊断有较高价值,其中CA199价值最高,灵敏度和特异度分别为76.2%和74.8%。CA199、CA242、CA125随着胰腺癌的病程进展而逐步升高。结论血清CA199、C242和CA125的检测对胰腺癌的诊断和判断预后有价值。 Objective To investigate the expression of serum tumor markers in pancreatic carcinoma and to assess the value of serum tumor markers in the diagnosis and prognosis of pancreatic carcinoma. Methods Five serum tumor markers including AFP, CEA, CA199, CA125 and CA242 were detected in 95 patients with pancreatic carcinoma by chemi-luminescence immunoassay (CLI) and enzyme linked immunosorbent assay (ELISA), 80 patients with other malignant tumor and 65 patients with benign disease served as controls. Five tumor markers in pancreatic carcinoma diagnosis for TNM staging were compared. The value of tumor markers for prognosis was analyzed. Results Among these 5 kinds of tumor marker, CA199, CA125, CA242 were valuable in diagnosis of pancreatic carcinoma, and CA199 was the most valuable one, whose sensitivity and specificity were 76.2 % and 74.8 % respectively. CA199, CA125, CA242 were increased with progression of pancreatic carcinoma. Conclusion Serum CA199, CA125 and CA242 are the preferred tumor markers to be used in the diagnosis and prognosis of pancreatic carcinoma.
出处 《肿瘤研究与临床》 CAS 2008年第11期754-756,共3页 Cancer Research and Clinic
关键词 胰腺肿瘤 肿瘤标记 生物学 Pancreatic neoplasms Tumor markers, biology
  • 相关文献

参考文献6

二级参考文献17

  • 1Haglund C,Lundin J,Kuusela P,et al. CA242,a new tumout ma rker for pancreatic cancer:a comparison with CA19-9,CAS0 and CEA. Br J Cancer, 1994,70: 487-492
  • 2Pasanen PA,Eskelinen M, Partanen K,et al. Clinical evaluation of a new serum tumour marker CA242 in pancreatic carcinoma. Br J Cancer, 1992,65: 731-734
  • 3Rothlin MA,Joller H,Largiader F. CA242 is a new tumour mar ker for pancreatic cancer. Cancer, 1993,71: 701-707
  • 4Faraggi D, Reiser B. Estimation of the area under the ROC curve. Stat Med, 2002,21:3093-3106.
  • 5Nazli O,Bozdag AD, Tansug T, et al. The diagnostic importance of CEA and CA19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology, 2000, 47:1750-1752.
  • 6Park SH, Goo JM, Jo CH. Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J Radiol,2004,5:11 18.
  • 7Faraggi D, Reiser B, Schisterman EF ,et al. ROC curve analysis for biomarkers based on pooled assessments. Stat Med, 2003,22:2515-2527.
  • 8Mazurek S, Boschek BC, Hugo F, et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol, 2005,15: 300-308.
  • 9Ventrucci M, Cipolla A, Racchini C, et al. Tumor M2-pyruvate Kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci, 2004, 49 : 1149-1155.
  • 10Cerwenka H ,Aigner R ,Bacher H ,et al. Tu M2-PK (pyruvate kinase type tumor M2 ) ,CA199 and CEA in patients with benign ,malignant and metastasizing pancreatic lesions. Anticancer Res, 1999,19 : 849-852.

共引文献44

同被引文献57

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部